Grölz Daniel, Hauch Siegfried, Schlumpberger Martin, Guenther Kalle, Voss Thorsten, Sprenger-Haussels Markus, Oelmüller Uwe
QIAGEN GmbH, Research & Development, QIAGEN Strasse 1, 40724 Hilden, Germany.
Curr Pathobiol Rep. 2018;6(4):275-286. doi: 10.1007/s40139-018-0180-z. Epub 2018 Oct 18.
PURPOSE OF REVIEW: Liquid biopsy analyses based on circulating cell-free nucleic acids, circulating tumor cells or other diseased cells from organs, and exosomes or other microvesicles in blood offer new means for non-invasive diagnostic applications. The main goal of this review is to explain the importance of preserving whole blood specimens after blood draw for use as liquid biopsies, and to summarize preservation solutions that are currently available. RECENT FINDINGS: Despite the great potential of liquid biopsies for diagnostics and disease management, besides non-invasive prenatal testing (NIPT), only a few liquid biopsy applications are fully implemented for routine in vitro diagnostic testing. One major barrier is the lack of standardized pre-analytical workflows, including the collection of consistent quality blood specimens and the generation of good-quality plasma samples therefrom. Broader use of liquid biopsies in clinical routine applications therefore requires improved pre-analytical procedures to enable high-quality specimens to obtain unbiased analyte profiles (DNA, RNA, proteins, etc.) as they are in the patient's body. SUMMARY: A growing number of stabilizing reagents and dedicated blood collection tubes are available for the post-collection preservation of circulating cell-free DNA (ccfDNA) profiles in whole blood. In contrast, solutions for the preservation of circulating tumor cells (CTC) that enable both, enumeration and molecular analyses are rare. Solutions for extracellular vesicle (EV) populations, including exosomes, do not yet exist.
综述目的:基于循环游离核酸、循环肿瘤细胞或来自器官的其他病变细胞以及血液中的外泌体或其他微囊泡的液体活检分析为非侵入性诊断应用提供了新方法。本综述的主要目的是解释采血后保存全血标本用作液体活检的重要性,并总结目前可用的保存溶液。 最新发现:尽管液体活检在诊断和疾病管理方面具有巨大潜力,但除了无创产前检测(NIPT)外,只有少数液体活检应用在常规体外诊断检测中得到全面实施。一个主要障碍是缺乏标准化的分析前工作流程,包括采集质量一致的血液标本以及从中生成高质量的血浆样本。因此,要在临床常规应用中更广泛地使用液体活检,就需要改进分析前程序,以获得高质量的标本,从而获得与患者体内一致的无偏差分析物谱(DNA、RNA、蛋白质等)。 总结:越来越多的稳定试剂和专用采血管可用于全血中循环游离DNA(ccfDNA)谱的采集后保存。相比之下,能够同时进行循环肿瘤细胞(CTC)计数和分子分析的保存溶液很少。针对包括外泌体在内的细胞外囊泡(EV)群体的保存溶液尚不存在。
Mol Aspects Med. 2020-4
J Hematol Oncol. 2022-9-12
Diagnostics (Basel). 2025-1-4
Clin Mol Hepatol. 2025-2
Front Oncol. 2024-5-21
World J Gastroenterol. 2024-3-28
J Exp Clin Cancer Res. 2023-8-4
Cancer Genet. 2018-12
J Transl Int Med. 2017-9-30